Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia, Milan, Italy, presents 7-year overall survival results from the Phase III SOLO1/GOG-3004 trial (NCT01844986) where it was demonstrated that maintenance olaparib provided sustained benefit beyond the end of treatment in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Following 7 years, 67.0% of olaparib patients vs 46.5% of placebo patients were alive and no new safety signals were detected. This, in combination with findings from PAOLA-1 (NCT02477644) supports the use of maintenance olaparib in this setting. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
